InBrain Pharma Secures €1.8M to Propel Groundbreaking Parkinson’s Treatment from Lille Research Team

InBrain Pharma is excited to announce the successful closure of a new funding round with a raise of €1,800,000, marking a significant step forward in the company’s journey toward advancing innovative treatments for central nervous system disorders. Founded in 2018, InBrain Pharma is a trailblazer in the biotech industry, focusing on conditions such as advanced Parkinson’s Disease through its groundbreaking therapeutic approach. The company leverages an exclusive worldwide patent license, obtained through an agreement with the Northern France TTO, to further develop the pioneering research initiated by Pr David DEVOS and Pr Caroline MOREAU at the Lille Neuroscience & Cognition UMR-S 1172 INSERM and the Lille University Hospital. The fresh capital injection not only reinforces InBrain Pharma’s mission to transform treatment paradigms for complex CNS disorders but also builds on its impressive track record of innovation and achievement. With a total of €4.4 million raised so far from both dilutive and non-dilutive sources, the funds have already facilitated early-stage clinical trials. Notably, the first phase I/IIb DIVE-I clinical trial was conducted on 12 patients, and the recently obtained results have paved the way for further clinical development. This latest funding milestone will be strategically allocated to support ongoing clinical trials, enhance research and development efforts, and accelerate regulatory activities. InBrain Pharma is committed to harnessing scientific excellence and clinical innovation to deliver meaningful therapeutic solutions. The dedicated team continues to work closely with leading academic and clinical partners, setting a new standard in the treatment of CNS disorders and creating promising prospects for patients worldwide.